companydata.dkNovo Nordisk Research Center Gladsaxe ApS: Financial statements 2019
CVR: 39119374
Novo Nordisk Research Center Gladsaxe ApS (CVR 39119374) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 25,623,833 and a net result of DKK 14,426,111 compared with DKK 9,820,500 the year before. That is an increase of 71.4% compared with the year before. Equity amounted to DKK 18,302,167. The solvency ratio was 64.8%. The company had 5 employees in the financial year.
- Gross Profit
- 25,623,833 kr.
- Profit/Loss
- 14,426,111 kr.
- Equity
- 18,302,167 kr.
- Total Assets
- 28,230,570 kr.
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 25.6 mio. | 14.4 mio. | 18.3 mio. | 5 |
| 2018 | - | 14.9 mio. | 9.8 mio. | 52 t. | 1 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2019
Novo Nordisk Research Center Gladsaxe ApS has published its annual report for 2018. Gross profit came to DKK 14,947,235, and the net result was DKK 9,820,500.
As of May 21, 2019, EY Godkendt Revisionspartnerselskab has been appointed auditor of Novo Nordisk Research Center Gladsaxe ApS.
About Novo Nordisk Research Center Gladsaxe ApS
Novo Nordisk Research Center Gladsaxe ApS is a Danish company of the type Anpartsselskab based in Bagsværd, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Embark Biotech ApS and Embark Biotech IvS. The management consists of Rikke Ryttergaard Andersen. The company is owned by NOVO NORDISK A/S. The company has 7 employees. In 2025, the company reported a gross profit of DKK -1,000 and a net result of DKK 48,000 compared with DKK 6,174,000 the year before. Equity amounted to DKK 807,000.